CURE Award
Jong M. Rho, MD / Barrow Neurological Institute, Phoenix, AZ
The major goal of this study is to evaluate brain slices prepared from human surgical specimens using a highly computerized multi-electrode recording technique, one that may provide clues as to how seizures begin and spread within the tissue, and subsequently determine if any currently available drugs can block the abnormal firing of HH cells.
Challenge Award, Funded by the Julie's Hope Award/CURE
Gabriella D’Arcangelo, PhD / Rutgers University, Piscataway, NJ
Challenge Awards
Lionel Carmant, MD / CHU-Sainte-Justine, Montreal, Canada
Dr. Camant will evaluate whether this neuroprotective treatment improved long-term outcome by performing a developmental evaluation at 24 months and another one at 30 months post-diagnosis for autism.
CURE Award
Jingqiong Kang, MD, PhD / Vanderbilt University Medical Center, Nashville, TN
This project seeks to understand the role of a particular epilepsy gene mutation (GABAA receptor subunits) in this process.
CURE Award, Funded by the Central New York Award, in Memory of Christopher Donalty and Kyle Coggins
H. Steve White, PhD / University of Utah
The purpose of this study is to characterize the clinical and electrographic seizure phenotype, determine virus-immune-CNS parameters involved in seizure development and seizure susceptibility and assess the impact of acute viral infection on seizure threshold and the development of epilepsy.
CURE Award, Funded by the Rhode Island Award
Michael J. Kubek, PhD / Indiana University School of Medicine, Indianapolis, IN
The goal of this Dr. Kubek’s research is to develop a neuropeptide-containing nanoparticle nasal spray for seizure therapy.
Quest Awards
Karin Borges, PhD / Texas Tech University Health Sciences Center, Amarillo, TX
Dr. Borges will test, in mice, whether an anaplerotic diet can inhibit seizures.
Multidisciplinary Awards
Gregory Mathews, MD, PhD / Vanderbilt University Medical Center
This one-year collaborative effort between Dr. Poulsen (a molecular virologist) and Dr. Mathews (a clinical epileptologist and basic neuroscientist) will explore the use of viral gene technology for enhancing GABA, offering the promise of new and less debilitating therapeutic options for epilepsy patients.
Quest Awards, Funded by the UCB Diamond Sponsorship Award
Christophe Bernard, PhD / INSERM, Marseille, France
By boosting HCN activity in animal models of epilepsy, using specific drugs or via genetic technology, this study may lead to new approaches to controlling seizures with the potential of also restoring cognitive function.
